AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States, University College London Hospitals NHS Foundation Trust, London, United Kingdom, University College London, London, United Kingdom
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
4 University College London, London, United Kingdom
5 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
6 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
7 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
8 University College London, London, United Kingdom
9 University College London, London, United Kingdom
10 University College London, London, United Kingdom
11 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
12 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
15 NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom, University College London Hospitals NHS Foundation Trust, London, United Kingdom, University College London, London, United Kingdom
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
CAR-T cells require lymphodepletion to optimise expansion and persistence. Fludarabine and cyclophosphamide are widely used, whilst alemtuzumab is often added before allogeneic products where intensified lymphodepletion mitigates rejection risk. Alemtuzumab’s long half-life can eliminate infused therapeutic T cells. Current strategies address this by CD52 knock out (KO). We hypothesise that loss of CD52 compromises T cell expansion and that selective editing of the alemtuzumab-binding epitope could confer resistance while preserving CD52 expression and function.
To develop an epitope editing (EE) approach that abrogates alemtuzumab binding whilst preserving CD52 expression, we screened overlapping base and prime editing libraries targeting the alemtuzumab binding region of CD52 in K562 and primary T cells. Two amino acid substitutions, Ser33Gly and Ser34Gly (achievable with both base and prime editing), were identified as sufficient to abolish alemtuzumab binding. Flow cytometry confirmed loss of binding (mean 97% reduction), while preserving detection by a non-overlapping CD52 antibody, consistent with maintained surface expression. In silico structural modelling indicated that p.Ser33Gly and p.Ser34Gly edits does not perturb the CD52–Siglec-10 interaction and that these novel epitopes were non-immunogenic. Immunogenicity was assessed in vitro using a peptide-based stimulation assay to detect low-frequency antigen-specific T cell responses. Flow cytometric analyses revealed negligible CD8+ IFN-γ, TNF-α or CD137 responses following stimulation with either WT or EE CD52 peptides compared to positive control peptide pools.
We next determined whether loss of antibody binding was sufficient to protect T cells from alemtuzumab. CD52 EE and KO T cells were similarly protected against complement dependent cytotoxicity (WT T-cell death 77%, versus 35.1% epitope edited and 34.7% CD52 KO, p=0.001). Adoptive transfer experiments in NSG mice comparing mixed chimeras of WT, EE or KO T cells demonstrated that both CD52 EE and KO T cells were resistant to alemtuzumab-mediated depletion, but that EE cells consistently outcompeted KO cells after selective pressure. Recovery of EE cells was greater in both spleen and bone marrow compared to KO (n=6; spleen p<0.001, bone marrow p=0.001), indicating that preservation of CD52 improved post-transfer fitness or persistence beyond antibody resistance alone.
Sialylated CD52 engages inhibitory siglec receptors implicated in macrophage immune evasion and macrophage-mediated clearance is recognised as a barrier to allogeneic T cell persistence. Therefore, we investigated whether retention of CD52 led to reduced phagocytosis which could account for our observations. In PhRODO-based assays, macrophage uptake of CD52 KO T cells was increased relative to WT cells (p=0.01), whereas uptake of EE cells was comparable to WT. In vivo, macrophage depletion with clodronate liposomes reduced alemtuzumab-mediated clearance and allowed survival of unedited CD52-positive T cells, establishing macrophages as major effectors of alemtuzumab activity in this model. However, EE cells continued to engraft better than KO cells after clodronate treatment, indicating that reduced macrophage uptake contributes to, but does not fully account for, the advantage of preserving CD52 expression.
To confirm the utility of alemtuzumab as conditioning, we compared no treatment to alemtuzumab and cyclophosphamide in human CD52 transgenic C57BL/6 mice. Alemtuzumab resulted in 14-fold T-cell, 8-fold B-cell depletion while sparing myeloid cells compared to untreated controls. Congenic CD45.1 donor T cell engraftment in blood and spleen was greater after alemtuzumab conditioning compared to untreated (p = 0.007), alemtuzumab-treated WT (p = 0.006), or no-transfer control (p = 0.001) mice, and was comparable to cyclophosphamide conditioning (p = 0.18).
Finally, demonstration of epitope edited CAR-T function was performed with anti-CD19 CAR-T in an NSG NALM6 xenograft tumour mouse model. CD52 EE CD19 CAR-T cells retained anti-leukaemia activity equivalent to unedited CAR-T cells and survived alemtuzumab exposure in vivo, demonstrating compatibility with CAR-T effector function and antibody-mediated selection.
These data establish CD52 epitope editing as an expression-preserving strategy for alemtuzumab-compatible CAR-T therapy. These findings position CD52 EE as a biologically superior replacement for CD52 KO in universal CAR-T platforms.
DISCLOSURES
Thomas Andrew Fox, MD PhD: No relevant conflicts of interest to declare.